home - Research - Past Research
 

Notice Board Topics

Europain consortium receives EU and industry funding and begins five year research into better treatments for chronic pain Europain, a public-private consortium funded by the Innovative Medicines Initiative (IMI), announced today the launch of a five-year research project to understand and improve treatment of chronic pain. The project will receive 6M€ from the IMI as well as 12.5M€ in kind contribution from the European Federation of Pharmaceutical Industries and Associations (EFPIA) over the coming five years.

One in five adults suffers from chronic pain. This constitutes a major cause of long-term sick leave and forced early retirement, placing a great financial burden on both individuals and healthcare systems. Despite extensive research programmes by biopharmaceutical companies and academia, there remains a need for treatments that are more effective and with fewer side-effects.

Europain has established an international team of leading researchers and clinicians from both academia and industry to undertake multidisciplinary translational research. This team aims to increase the understanding of chronic pain mechanisms, help to develop novel analgesics, and develop better biomarkers for pain. Their ultimate goal is to improve the lives of people suffering from chronic pain.

During the five-year project, Europain will undertake a large number of preclinical and clinical studies. The program will be delivered through collaboration between laboratories in the Europain network, sharing resources to improve the value derived from the budget. Results will be made public during and after the project, ensuring that the knowledge created can be widely applied to the development of better therapies for patients suffering from chronic pain.

King’s College London, the managing entity of Europain and the academic lead institution will contribute to both the pre-clinical and clinical aspects of the project. One role will be to study the expression of potential pain mediators in both animal models of pain and samples from patients suffering from chronic pain. The role of novel pain mediators will then be investigated using an array of techniques ranging from cell culture to quantitative sensory testing in humans.

Professor Steve McMahon, who along with Dr Dave Bennett will be running the project at King’s, comments: ‘There are some big questions facing the pain field at the moment and this consortium, drawing on the skills and expertise of both academia and industry, is in a unique position to address them’.

The consortium network involves scientists representing 12 renowned European Universities: King’s College London (Academic lead), University College London, Imperial College London, the University of Oxford, the Christian-Albrechts-University of Kiel, the Medical Faculty Mannheim/Heidelberg University, the Technische Universität München, the Goethe University of Frankfurt, the BG University Hospital Bergmannsheil/Ruhr University Bochum, the University Hospitals of Aarhus, Rigshospitalet Copenhagen, University of Southern Denmark, the SME Neuroscience Technologies from Barcelona, and the research resources and expertise of Europe’s most active pharmaceutical companies working in the field of analgesics, including AstraZeneca (co-ordinator), Boehringer-Ingelheim, Eli Lilly, Esteve, Pfizer, Sanofi-Aventis, UCB Pharma.

About the Innovative Medicines Initiative

IMI is a unique Public-Private Partnership (PPP) between the pharmaceutical industry represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Union represented by the European Commission.
www.imi.europa.eu.
News, Videos and Features News

Chronic pain: the search for a killer

Researchers engaging with local communities

Researchers’ discovery of why sunburn hurts reveals possible target for new pain relief drugs

New award funding of LPC

UK researchers tackle pain

Imperial College and the London Pain Consortium partner with a Japanese chemical company to fight chronic pain

Videos

Walking on Fire click here

Features

London Pain Consortium: key Discoveries

Reserachers: Pain killers click here

Painstaking research - tackling chronic pain click here

The London Pain Consortium making a difference
Seminar Series There are currently no seminars scheduled.…
 
Past Research
Data mining to reveal potentially novel genes and biological processes involved in the pain response
DNA microarrays are a new and promising biotechnology which allow the monitoring of expression levels in cells for thousands of genes simultaneously. To characterise the molecular events underlying neuropathy and its chronic pain, the London Pain Consortium is using microarrays to monitor expression of genes in the DRG and spinal cord tissues in animal pain models. It is the aim of this project to explore expression data generated by microarrays to investigate the molecular signature of neuropathic pain. Specifically, different approaches to clustering microarrays expression data aiming at grouping genes with similar expression pattern will be investigated and ultimately assessed using biological information. Functional annotation of the genes being studied will be a further aim to the project in order to make the validation of clustering efforts possible and provide clues to function of those genes relevant to the pathology being studies as identified by the analysis of microarray data. The project will also aim to build a database facility which will store descriptions of microarray experiments conducted by the consortium, the outcome of the datamining analysis as well as the functional annotation of genes of interest. A final target to the project will be to assess one of the technical limitations of microarray technology which consists of the limitation in the amount of extracted RNA. In this regard, amplifying RNA target for microarray profiling will be assessed.